NCT05504187View on ClinicalTrials.gov

Study to Evaluate Safety, Tolerability and Pharmacodynamics of KP104 in Participants With Thrombotic Microangiopathy Secondary to Systemic Lupus Erythematosus

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

April 30, 2027

Conditions
Systemic Lupus Erythematosus
Interventions
DRUG

KP104

KP104 will be administered.

Sponsors
All Listed Sponsors
lead

Kira Pharmacenticals (US), LLC.

INDUSTRY

NCT05504187 - Study to Evaluate Safety, Tolerability and Pharmacodynamics of KP104 in Participants With Thrombotic Microangiopathy Secondary to Systemic Lupus Erythematosus | Biotech Hunter | Biotech Hunter